Eone Diagnomics Genome Center Co., Ltd. Q3 revenue KRW 1.3 billion, operating loss of KRW 0.7 billion
EAI summary · Not investment advice
EDGC sold KRW 1.3 billion in the third quarter and lost KRW 0.7 billion from its main business; sales fell 29.5% from a year earlier and rose 3.3% from the prior quarter.
Operating profit · 3 months
KRW -704.5 million
Key facts
- Revenue (3 months)
- KRW 1.3 billion
- Net income (3 months)
- KRW -1.4 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 1.8 billion
- Revenue (year to date)
- KRW 4.1 billion
- Operating profit (prior-year 3 months)
- KRW -415.3 million
- Operating profit (year to date)
- KRW -2.7 billion
- Net income (prior-year 3 months)
- KRW -436.3 million
- Net income (year to date)
- KRW 22.5 billion
Commentary
AI commentary · Not investment advice
What happened
EDGC reported its consolidated results for the third quarter of 2026. Sales for the 3 months were KRW 1.26 billion. In the same 3 months a year earlier, sales were KRW 1.79 billion. Year-to-date sales were KRW 4.09 billion.
In the company's terms
Operating profit (profit from the core business) for the 3 months was KRW -0.70 billion. A year earlier it was KRW -0.42 billion. The year-to-date figure is KRW -2.72 billion.
What changes for shareholders
Net income (the final profit after all costs and taxes) for the 3 months was KRW -1.42 billion. A year earlier it was KRW -0.44 billion. The year-to-date figure is KRW 22.54 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist